Mr. Charbonneau is a General Partner of Skypoint Capital Corporation and is a principal of Skypoint Telecom Fund II (collectively, "Sykpoint"). Prior to Skypoint, he was a senior executive with Newbridge Networks, ("Newbridge"), a telecommunications networking company, where he played a key role during the company's period of extraordinary growth and success. He joined Newbridge in its early days as chief financial officer and over the next 13 years was promoted to the positions of Executive Vice-President, President and Chief Operating Officer, and Vice-Chairman. Mr. Charbonneau was also a member of the Newbridge board of directors from 1996 until 2000. As the CFO of Newbridge, he led the company's successful cross-border IPO in 1989 and its second cross-border offering three years later. As Vice-Chairman, he focused on enhancing the company's relations with key external stakeholders. While at Newbridge, he was instrumental in establishing the Affiliates Program and was involved in the funding of more than 40 affiliated companies. In addition to sitting on a number of private company boards, Mr. Charbonneau currently serves on the board of directors of a number of public companies, including Mitel Networks, March Networks Corporation, Canadian Broadcasting Corporation, CounterPath Corporation and TrueContext Corporation. Mr. Charbonneau is a member of the Institute of Chartered Accountants of Ontario. In June 2003, he was elected a Fellow of the Institute in recognition of his outstanding career achievements and leadership contributions to the community and his profession. He holds a Bachelor of Science from the University of Ottawa and an MBA from the University of Western Ontario. Mr. Charbonneau also holds the ICD.D certification, having completed the Directors' Education Program of the Institute of Corporate Directors of Canada.
Dr. Mitchell H. Gold currently serves as executive chairman of Dendreon Corporation's Board of Directors. Previously, he served as president and chief executive officer of Dendreon since 2003, as well as vice president of business development and as chief business officer when he joined Dendreon in 2001. In April 2010 � after more than 15 years of research and development, 15 clinical trials, and more than $1 billion raised � Dendreon received approval from the FDA for the world's first autologous cellular immunotherapy, PROVENGE� (sipuleucel-T). Dr. Gold grew the company from having a market capitalization of $40 million to one of nearly $2 billion, establishing Dendreon as one of the largest biotech companies in the world. Prior to joining Dendreon, Dr. Gold previously served as vice president of business development and vice president of sales and marketing for Data Critical Corporation, a company engaged in wireless transmission of critical healthcare data, now a division of GE Medical. Dr. Gold was the president, chief executive officer, and a co-founder of Elixis Corporation, a medical information systems company. Dr. Gold currently serves on the board of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute. Dr. Gold received his B.S. from the University of Wisconsin-Madison and his M.D. from Rush Medical College in Chicago. Dr. Gold was a resident physician in the Department of Urology at the University of Washington.
Dr. Hermiston is Vice President, Biologics Research, U.S. Innovation Center Site Head for Bayer HealthCare Pharmaceuticals. Dr. Hermiston leads the US biologics research team at Bayer's world-wide pharmaceutical research organization and oversees the operation of Bayer's West Coast research center. With a biotechnology career spanning nearly two decades, Dr. Hermiston has published more than 50 research papers and reviews and holds over 10 patents. Prior to joining Bayer, Dr. Hermiston was the scientific director for the global department of gene therapy research and gene technologies for Berlex Biosciences and its Germany-based parent company, Schering AG. Dr. Hermiston also served in roles of increasing responsibility with Onyx Pharmaceuticals and completed a National Institutes of Health (NIH) fellowship in microbiology and immunology at St. Louis University School of Medicine. Dr. Hermiston holds a Ph.D. in molecular virology from the University of Iowa and a bachelor's degree in microbiology from Iowa State University.
Mr. Mulcahy has been a Director of the Company since its inception in April, 2006. Mr. Mulcahy is currently the Chairman and Chief Executive Officer of American Solar Direct; a distributed generation company, that sells, finances, constructs and services Photo Voltaic Solar Systems. Formerly he was the Chief Executive Officer of Just Energy Income Fund, Toronto, Ontario, a publicly-traded income trust with sales of over 2 billion dollars; as well he sits on the board of Magellan Fuel. He has been involved in the deregulation of natural gas and electricity in Canada and the United States for 20 years.
Ken Newport was appointed to Jennerex's board in 2007. A chartered accountant, entrepreneur and life sciences business executive, Mr. Newport served as senior vice president and executive committee member at PRA International Inc. for three years until his retirement in 2005. In the mid-nineties he was co-founder and president of CroMedica Inc., a clinical trials contract research organization which was sold to PRA International in 2002. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is a member of the Institute of Corporate Directors and also serves on the corporate boards of The Opmedic Group and Medgenesis Therapeutics Inc. Mr. Newport earned Honours B.A. and Masters of Accounting degrees from the University of Waterloo.
Dr. Stern is Executive Director of the Jewish General Hospital and professor of Surgery at McGill University. Most recently he was Vice President of The Ottawa Hospital Regional Cancer Centre and, the Provincial Head of Surgical Oncology with Cancer Care Ontario. Originally from Toronto, Dr. Stern completed his undergraduate medical education and surgical training at the University of Toronto, followed by a Research Training Fellowship at the London Hospital Medical College in London, England. He moved his practice to Ottawa in June 1994, to undertake the new roles of Surgeon-in-Chief at the Ottawa Civic Hospital, and subsequently The Ottawa Hospital (amalgamation-1998) and, as Chairman of the Department of Surgery at the University of Ottawa. In August 2000, Dr. Stern began a new challenge as the CEO of the Ottawa Regional Cancer Centre, which in January 2004 became a large integrated program in The Ottawa Hospital of the full spectrum of Cancer Services, Research and Education. Dr. Stern's clinical focus is colorectal cancer, and he intends to continue, in a limited fashion, to teach students. He holds an appointment as Professor of Surgery at McGill University. In addition, Dr. Stern had the opportunity to work with and preside over the Canadian Oncology Society, the Canadian Society of Surgical Oncology and the Integration Group of the Canadian Strategy for Cancer Control as it developed into a National Council. He now sits on the Advisory Board of the Canadian Partners Against Cancer.
Dr. Huh, joined the Company's Board of Directors on January 1, 2010. He is Chairman of Geron Corporation and BiPar Sciences, Inc. Dr. Huh has been involved in the formation and management of multiple healthcare companies. Most recently Dr. Huh was CEO of BiPar Sciences Inc. where he led the merger of BiPar with Sanofi-Aventis. Dr. Huh was previously a member of the board and Chief Operating Officer of Nektar Therapeutics Inc., a drug development company focused on oncology, CNS/pain, diabetes and infectious diseases. At Nektar, Dr. Huh led partnerships with major pharmaceutical companies, including Bayer, Roche, Baxter, Novartis, and Pfizer. As an industry leader, Dr. Huh speaks frequently on innovation, entrepreneurship, and biotechnology strategies. Dr. Huh was formerly a Partner at McKinsey and Co., as a leader in the biotechnology sector. Dr. Huh holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a bachelor's degree in biochemistry from Dartmouth College.